Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|August 23, 2023

Importance of Long-Term Safety Data in Plaque Psoriasis Treatment

Author(s)Alexa Hetzel, MS, PA-C, Jennifer Conner, MPAS, PA-C, Terry Faleye, MPAS, PA-C

Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.

Episodes in this series

EP. 1 The Role of Nurse Practitioners and Physician Assistants in Managing Plaque Psoriasis

EP. 1 The Role of Nurse Practitioners and Physician Assistants in Managing Plaque Psoriasis

EP. 2 Evolution of Plaque Psoriasis

EP. 2 Evolution of Plaque Psoriasis

EP. 3 Efficacy of Deucravacitinib in Plaque Psoriasis

EP. 3 Efficacy of Deucravacitinib in Plaque Psoriasis

EP. 4 Approaches to Treatment of Plaque Psoriasis

EP. 4 Approaches to Treatment of Plaque Psoriasis

EP. 5 Importance of Quick Response to Treatment for Patients With Plaque Psoriasis

EP. 5 Importance of Quick Response to Treatment for Patients With Plaque Psoriasis

EP. 6 Metrics to Determine Disease Clearance in Plaque Psoriasis

EP. 6 Metrics to Determine Disease Clearance in Plaque Psoriasis

EP. 7 Addressing Unmet Needs in Psoriasis Treatment

EP. 7 Addressing Unmet Needs in Psoriasis Treatment

EP. 8 Patient Case #1: 50-Year-Old Female With Plaque Psoriasis

EP. 8 Patient Case #1: 50-Year-Old Female With Plaque Psoriasis

EP. 9 Escalating Treatment From Topical to Systemic in Plaque Psoriasis

EP. 9 Escalating Treatment From Topical to Systemic in Plaque Psoriasis

EP. 10 Systemic Treatment Options in Plaque Psoriasis

EP. 10 Systemic Treatment Options in Plaque Psoriasis

EP. 11 Importance of Long-Term Safety Data in Plaque Psoriasis Treatment

EP. 11 Importance of Long-Term Safety Data in Plaque Psoriasis Treatment

EP. 12 Patient Case #2: 23-Year-Old Female With Plaque Psoriasis

EP. 12 Patient Case #2: 23-Year-Old Female With Plaque Psoriasis

EP. 13 Use of Systemic Treatment in Plaque Psoriasis

EP. 13 Use of Systemic Treatment in Plaque Psoriasis

EP. 14 Safety Profile of TYK2 Inhibitors in Plaque Psoriasis Treatment

EP. 15 Role of Advanced Practice Providers in Plaque Psoriasis Treatment Follow-Up

EP. 15 Role of Advanced Practice Providers in Plaque Psoriasis Treatment Follow-Up

EP. 16 Patient Case #3: 40-Year-Old Woman With a 10-Year History of Plaque Psoriasis

EP. 16 Patient Case #3: 40-Year-Old Woman With a 10-Year History of Plaque Psoriasis

EP. 17 Treating Comorbidities With Plaque Psoriasis

EP. 17 Treating Comorbidities With Plaque Psoriasis

EP. 18 Unmet Needs in the Treatment Spectrum of Plaque Psoriasis

EP. 18 Unmet Needs in the Treatment Spectrum of Plaque Psoriasis

EP. 19 Take-Home Pearls on the Management of Plaque Psoriasis

EP. 19 Take-Home Pearls on the Management of Plaque Psoriasis

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Guselkumab's CD64 Binding Offers Targeted IL-23 Inhibition in PsA

ByPhilip J. Mease, MD,Kaitlyn Bader, Assistant Managing Editor

July 10th 2026

5 Dermatology Approvals to Know from the First Half of 2026

ByPatrick Campbell

July 10th 2026

Why Do Some Psoriasis Patients Respond Differently to Biologics? New Study Offers Clues

ByShannon Heaning, Content Associate

July 7th 2026

Smoking Associated with Increased Nail Psoriasis Severity, Case-Control Study Finds

ByMarie Bosslett, Assistant Editor

July 7th 2026

First-in-Class Oral Piclidenoson Reaches Pivotal Phase 3 Enrollment Milestone in Plaque Psoriasis

ByShannon Heaning, Content Associate

July 6th 2026

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

Study Suggests Non-Ablative Fractional Laser Reverses Epigenetic Signatures of Skin Aging

Bempikibart Shows Positive Phase 2a Results in Alopecia Areata

The Gut-Skin Axis: New Evidence Links Microbiota to Skin Disease via Inflammatory Cytokines

Social Media Mythbusters: PDRN Serums

Roundtable Discussion Weighs Access and Adherence Challenges in Vitiligo Care